Immunotherapy treatment for newly diagnosed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an immunotherapy drug combination for people newly diagnosed with multiple myeloma who have had some response to initial treatment but still have signs of disease. The goal is to see if this approach can help eliminate remaining cancer cells and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed multiple myeloma and have received at least 4 cycles of a combination therapy (like a triplet or quadruplet) that includes an immunomodulatory drug (IMiD) and/or a proteasome inhibitor and/or an anti-CD38 antibody.
- Your disease must have responded to that therapy (at least a partial response), but you still have minimal residual disease (MRD) that is detectable with sensitive tests.
- You must be 18 years or older.
- You must be able to perform daily activities with minimal assistance (ECOG score 0 or 1; being a 2 only because of myeloma-related pain may be allowed after discussion).
- Your blood counts and organ function (kidney, liver, heart) must be within acceptable ranges, and you cannot have other serious illnesses or infections that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.